

Vladimir Semiglazov

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7218205/vladimir-semiglazov-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	21,807 citations	43 h-index	73 g-index
73 ext. papers	25,352 ext. citations	8.5 avg, IF	5.6 L-index

#	Paper	IF	Citations
66	Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005 , 366, 2087-106	4 ⁰	3823
65	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014 , 384, 164-72	4 ⁰	2177
64	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
63	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 25-32	21.7	1438
62	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 724-34	59.2	1242
61	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
60	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012 , 379, 633-40	4 ⁰	964
59	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet, The</i> , 2010 , 375, 377-84	4 ⁰	864
58	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2013 , 14, 461-71	21.7	687
57	Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. <i>Annals of Oncology</i> , 2001 , 12, 1527-32	10.3	540
56	Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5960-72	2.2	536
55	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2630-7	2.2	514
54	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , 2011 , 12, 236-44	21.7	500
53	Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1940-9	2.2	488
52	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology, The</i> , 2016 , 17, 791-800	21.7	408
51	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5314-22	2.2	402
50	Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1508-16	3.1	329

49	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology, The</i> , 2014 , 15, 489-538	1.7	316
48	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet Oncology, The</i> , 2014 , 15, 640-7	21.7	313
47	Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. <i>Annals of Oncology</i> , 2007 , 18, 1927-34	10.3	277
46	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 869-78	21.7	241
45	Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. <i>Cancer</i> , 2007 , 110, 244-54	6.4	233
44	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1719-25	2.2	211
43	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020 , 21, 519-530	21.7	159
42	Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2474-81	2.2	152
41	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. <i>Clinical Cancer Research</i> , 2014 , 20, 511-21	12.9	143
40	Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. <i>Lancet Oncology, The</i> , 2013 , 14, 962-70	21.7	143
39	Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. <i>Clinical Cancer Research</i> , 2005 , 11, 8715-21	12.9	135
38	Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4963-70	2.2	127
37	Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3877-84	2.2	116
36	Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 379-90	4.4	107
35	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014 , 25, 1979-1987	10.3	101
34	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 302-308	13.4	74
33	Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2014 , 25, 592-598	10.3	69
32	Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. <i>Familial Cancer</i> , 2007 , 6, 281-6	3	61

31	Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 6822-30	12.9	54
30	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 327-35	4.4	53
29	NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. <i>International Journal of Cancer</i> , 2005 , 114, 585-9	7.5	52
28	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 322-31	2.2	48
27	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 89-99	4.4	46
26	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. <i>International Journal of Cancer</i> , 2012 , 130, 2867-73	7.5	46
25	Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. <i>Journal of Developmental and Physical Disabilities</i> , 2002 , 25, 119-25		45
24	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
23	Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 469-75	5.7	39
22	A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. <i>Oncology Research and Treatment</i> , 2010 , 33, 504-11	2.8	38
21	Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 843-51	4.4	35
20	More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. <i>Medical Oncology</i> , 2011 , 28, 1260-3	3.7	30
19	CHEK2 1100delC mutation is frequent among Russian breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 99-102	4.4	30
18	First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥ 70 years treated in the ATHENA study. <i>Annals of Oncology</i> , 2012 , 23, 111-118	10.3	29
17	Aromatase in breast cancer tissue--localization and relationship with reproductive status of patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996 , 122, 495-8	4.9	26
16	RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 21-3	4.8	25
15	Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. <i>International Journal of Cancer</i> , 2007 , 121, 514-9	7.5	18
14	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009 , 18, 2-7	3.6	14

13	Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 589-597	10.3	12
12	Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed. <i>Clinical Breast Cancer</i> , 2014 , 14, 26-30	3	6
11	Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy. <i>Bulletin of Experimental Biology and Medicine</i> , 2004 , 138, 494-6	0.8	4
10	A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study). <i>Blood</i> , 2014 , 124, 5133-5133	2.2	4
9	Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2009 , 7, 2	2.3	3
8	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. <i>British Journal of Cancer</i> , 2019 , 120, 579-586	8.7	2
7	Endocrine metabolic disorders in patients with breast cancer, carriers of BRCA1 gene mutations. <i>Bulletin of Experimental Biology and Medicine</i> , 2012 , 152, 610-2	0.8	2
6	The role of digital mammography, scintimammography with 99m Tc-methoxyisobutylisonitrile (MIBI) and ultrasound in the diagnosis of multicentric breast cancer. <i>Opuholi Zenskoj Reproktivnoj Sistemy</i> , 2020 , 15, 12-22	0.3	2
5	SENTINEL LYMPH NODE BIOPSY IN EARLY BREAST CANCER: THE EXPERIENCE OF THE N.N. PETROV RESEARCH INSTITUTE OF ONCOLOGY. <i>Voprosy Onkologii</i> , 2017 , 63, 267-273	1.5	2
4	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.. <i>Frontiers in Oncology</i> , 2021 , 11, 827625	5.3	1
3	N3 category in the TNM classification of breast cancer needs to be defined more precisely. <i>Breast</i> , 1997 , 6, 217-220	3.6	
2	Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2003 , 136, 487-9	0.8	
1	Activity of aromatase in breast cancer tissue: Role of the cell substrate. <i>Bulletin of Experimental Biology and Medicine</i> , 1995 , 120, 1042-1045	0.8	